CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.

Peter MakhovJi A SohnIlya G SerebriiskiiRushaniya FazliyevaVladimir KhazakYanis BoumberRobert G UzzoVladimir M Kolenko

Published in: British journal of cancer (2020)

CRISPR/Cas9 LOF screening presents a promising approach to identify and target cellular factors involved in the resistance to anti-cancer therapeutics.

Keyphrases

crispr cas
renal cell carcinoma
genome wide
genome editing
dna methylation
small molecule
copy number